Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA (guselkumab) maintained or improved combined fistula remission through 48 weeks in adults with perianal fistulizing Crohn's disease. In the 100 mg q8w maintenance arm, combined fistula remission rose from 28% at Week 24 to 35% at Week 48, versus 10% on placebo at Week 24; more than 90% of randomized patients completed treatment through Week 48 with a safety profile consistent with the established TREMFYA profile.
Key figures
- Drug Name
- TREMFYA (guselkumab)
- Phase Of Trial
- Phase 3
- Placebo week24 remission
- 10%
- Treatment completion rate
- more than 90%
- Week24 remission 200mg q4w
- 27%
- Combined fistula remission 100mg q8w week24
- 28%
- Combined fistula remission 100mg q8w week48
- 35%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.